摘要
目的:系统评价银杏叶片治疗血管性痴呆的有效性及安全性。方法:检索PubMed、Cochrane Library、EMbase、中国知网、万方数据库、维普、中国生物医学数据库中关于银杏叶片治疗血管性痴呆的临床随机对照试验,时限为从建库至2020年07月。由2名研究者独立筛选文献、提取资料并评价纳入研究的偏倚风险后,采用RevMan 5.4软件进行Meta分析。结果:共纳入13项随机对照试验,共1 182例患者,其中治疗组593例,对照组589例。Meta分析结果显示:与对照组相比,银杏叶片治疗组在有效率[RR=1.27,95%CI(1.17,1.38),Z=5.54,P<0.00001]、简易智力状态检查量表(MMSE)[MD=3.29,95%CI(2.49,4.09),Z=8.06,P<0.00001]、日常生活能力评分(Barthel Index)[MD=7.84,95%CI(5.34,10.34),Z=6.14,P<0.00001]、长谷川痴呆量表(HDS)[MD=6.22,95%CI(5.27,7.17),Z=12.81,P<0.00001]方面,均改善更显著,但在不良反应发生率方面,差异无统计学意义。结论:银杏叶片单独使用具有改善认知功能和提高有效率的作用,联合其他改善认知药物具有协同增效作用,并且可以改善日常生活能力和临床痴呆程度,未发现其导致不良反应增多。但由于纳入研究质量较低,纳入文献数量较少,上述结论仍需更多高质量随机对照试验加以验证。
Objective: To evaluate the efficacy and safety of ginkgo biloba tablet in the treatment of vascular dementia. Methods: The clinical randomized controlled trials of ginkgo biloba tablet in the treatment of vascular dementia were searched in PubMed, Cochrane Library, EMbase, China knowledge Network, Wanfang Database, VIP and Chinese Biomedical Database from the establishment of the database to July 2020. After two researchers independently screened the literature, the data was extracted and the bias risk was evaluated, Meta analysis was carried out with RevMan 5.4 software. Results: A total of 13 randomized controlled trials were included, totally 1182 patients, including 593 patients in the treatment group and 589 patients in the control group. The results of Meta analysis showed: Compared with the control group, there were significant differences in the effective rate[RR=1.27,95%CI(1.17,1.38),Z=5.54,P<0.00001], mini mental state examination scale[MD=3.29,95%CI(2.49,4.09),Z=8.06,P<0.00001], activity of daily living score[MD=7.84,95%CI(5.34,10.34),Z=6.14,P<0.00001]and Hasegawa dementia scale[MD=6.22,95%CI(5.27,7.17),Z=12.81,P<0.00001]in the ginkgo biloba tablet treatment group. However, there was no significant difference in the incidence of adverse reactions. Conclusion: Ginkgo biloba tablet can improve the cognitive function and the effective rate. It has a synergistic effect when combined with other cognitive drugs, and can improve the ability to perform activities of daily living and the degree of clinical dementia, no increase in adverse reactions was observed. However, due to the low quality of included studies and a small number of included literatures, the above conclusions still need to be verified by more high-quality randomized controlled trials.
作者
樊飞燕
行文娟
冯雨菡
张运克
Fan Feiyan;Xing Wenjuan;Feng Yuhan;Zhang Yunke(Henan University of CM;The First Affiliated Hospital of Henan University of CM)
出处
《中药药理与临床》
CAS
CSCD
北大核心
2021年第2期167-172,共6页
Pharmacology and Clinics of Chinese Materia Medica
基金
国家自然科学基金资助项目(编号:81974564)。
